Liquid Biopsy ­– The key to cancer diagnostics, monitoring and treatment

Accelerating the commercialization of non-invasive tests for liquid biopsy of solid tumor cancers. (LIQ-BIOPSY)

Cancer is not one disease, but several – which partly explains the complexity and variability in treatment, management and prognosis of patients. In 2018, there were over 18 million people diagnosed with cancer, and more than 9 million deaths because of it1. By 2030, due to population growth and increased life expectancy, the number of new cases is expected to increase to 21 million, with the number of deaths rising to 13 million2. Cancer is defined as the uncontrollable growth of mutated (altered) cells, and an important factor contributing to cancer management and survival are the tools used today to diagnose, treat and monitor a person with cancer.

Indisputably, the key to effective cancer control and one of the global challenges to reducing the impact of cancer is diagnostic delays. If cancer is detected early, when the tumor is still small and hasn’t metastasized to other organs yet, chances of successful treatment are higher. Currently, cancer detection is achieved via screening and diagnostic tests. Screening tests are used as a first line of cancer detection to identify a small group of people that are high-risk of having cancer and to refer them for diagnostic tests. Screening tests are usually simpler and less invasive than diagnostic tests, which give a definite answer on whether the patient has cancer.

Screening procedures include colonoscopy for colorectal cancer; analysis of prognostic biomarkers like evaluating the CA-125 levels through a blood test for ovarian cancer; and medical imaging, such as a screening mammography for breast cancer. Screening tests can be useful as a first line of detection because of their simplicity, but some limitations exist as they could still be invasive, painful, or subject patients to harmful radiation. Additionally, not all cancers have a reliable screening test. Lastly, some screening tests have low specificity, and thus may unnecessarily refer many patients for intrusive diagnostic tissue biopsies. The biggest shortcoming of screening tests though, is that they detect cancer when it has become prominent – not during the early stages, where immediate response is critical and most beneficial.

Currently, traditional cancer diagnostics also face challenges related to feasibility (a tissue biopsy for a lung cancer may not always be achievable), and the delay in recovering from these invasive procedures which could further stress the immune system and compromise the efficiency of cancer therapy. Further limitations include the inability to obtain a fully accurate genomic picture of the tumor as this depends on the biopsy site and the cells collected. Advanced and metastatic cancers especially tend to be heterogeneous (composed of different genetic mutations), and therefore, a single biopsy from one tumor site may not represent the whole tumor.

Hence, an area of particular interest in the cancer field is the liquid biopsy test. Performed via a simple blood draw, a liquid biopsy test can detect circulating tumor DNA (ctDNA) released into the bloodstream from cancerous cells and tumors3. This ctDNA varies from ‘normal’ DNA as it has acquired genetic mutations related to the tumor. Therefore, detection of ctDNA can be key for early cancer detection and diagnosis.

Liquid biopsy tests offer advanced sensitivity than conventional detection methods because ctDNA has tumor characteristics from all cancerous sites in the body and can assess tumor heterogeneity that could otherwise go unnoticed in a traditional tumor biopsy. By providing an accurate picture of the disease, liquid biopsy testing could help in providing tumor-specific treatment via targeted therapies. Looking at the particular mutations in a patient’s sample will allow their physician to determine the most appropriate treatment option and prescribe therapies that are the most effective for the specific mutations present. This has the potential to cause less side effects for the patients, and will undoubtedly provide them with the best chances of successful treatment. Additionally, liquid biopsy can work as a prognostic tool, tracking and assessing the risk of relapse and prognosis of patients, and of acquired treatment resistance over the course of therapy via serial blood-draws which would examine the changing ctDNA. Liquid biopsy is the ideal test for serial testing, due to its fast, painless and safe application – this would not be possible with conventional cancer diagnostics due to the tests’ invasiveness. For example, a study on colorectal cancer has demonstrated that ctDNA levels indicating recurrence were detected on average 10 months before cancer relapse was picked up by other methods4. This indicates that liquid biopsy can monitor tumor dynamics and detect disease much earlier than other means, which would be extremely beneficial for quick medical action and effective treatment that could prove life-saving.

Lastly, the key advantage of liquid biopsy testing is how early the test can detect cancer. Compared to current screening and detection methods that confirm the presence of cancer typically after the onset of symptoms, a liquid biopsy can identify ctDNA presence in the bloodstream much earlier. This is integral in preventing metastasis and encouraging improved chances of treatment.

The presence of ctDNA in the bloodstream is well-known for over 20 years3. The extremely low volume of ctDNA compared to non-pathogenic DNA makes the design of a ctDNA test intricate and challenging. The story of ctDNA is similar with that of cell-free fetal DNA (cffDNA). More than two decades have passed since the discovery of cff-DNA in 1997, to the routine implementation of non-invasive prenatal tests (NIPT) to pregnant women of all ages. Implementation of next generation sequencing for cell-free fetal DNA detection revolutionized prenatal testing by allowing for the detection of multiple aneuploidies, microdeletions and even single gene disorders prenatally; informing prospective parents and healthcare providers of the health of the unborn baby and allowing them to take informed decisions regarding management and possible treatment. With the leaps of technological advances we have witnessed in recent years, the wealth of information obtained and the ability of the scientific community to transform these into clinical actions, the application of liquid biopsy into clinical practice will soon be a reality that will benefit millions.

NIPD Genetics is currently developing a liquid biopsy assay for the detection of cancer using ctDNA. In line with NIPD Genetics’ vision of providing safe, sensitive and reliable tests, our liquid biopsy assay will provide valuable clinical utility for the detection of solid cancers, and would have applications in many clinical decision-making points such as early cancer detection, diagnosis, monitoring of tumor dynamics, identification of mutations for targeted therapy and assessment of treatment resistance. Leveraging our powerful technology, we aim to bring to the market an affordable and accurate liquid biopsy assay that will benefit and revolutionize cancer care worldwide. 70% of this research is funded by the Research and Innovation Foundation, Cyprus, under the program RESTART 2016-2020 after receiving the Seal of Excellence from the European Commission5 under the H2020 program.

References:

  1. World Health Organization Press Release (2018). ‘Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2008’. International Agency for Research on Cancer.
  2. World Health Organization (2019) ‘Key Statistics’,
  3. https://www.who.int/cancer/resources/keyfacts/en/
    Sorenson GD., et al. (1994) ‘Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiology, Biomarkers & Prevention; 3(1): 67-71
  4. Reinert T., et al. (2016) ‘Analysis of circulating tumor DNA to monitor disease burden following colorectal cancer surgery’. Gut; 65:625-634
  5. https://www.nipd.com/company/science/


Share
View All Posts

NIPD Genetics - Privacy Policy

General Statement

This Privacy Policy applies only to www.nipd.com and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.

If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.

NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.

Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.

You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus

NIPD Genetics Data Protection Officer can be reached at dpo@nipd.com

This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:

NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.

We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from www.nipd.com

Type of personal information NIPD Genetics may collect through its Sites

Information Collection And Use

We collect several different types of information for various purposes to provide and improve our Sites and services to you.

Personal Data

While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:

If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.

Cookies and Usage Data

Usage Data

We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

Tracking & Cookies Data

We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.

Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.

Examples of Cookies we use:

Session Cookies. We use Session Cookies to operate our Sites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the Sites

Keyword cookies. To understand how visitors discover the Sites.

Use of Data

www.nipd.com uses the collected data for various purposes:

Transfer of Data

Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

www.nipd.com will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.

NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:

Security of Data

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

Service Providers

We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

Analytics

We may use third-party Service Providers to monitor and analyze the use of our Sites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

Access to your personal data, correction, deletion, and Opting Out

You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer pdo@nipd.com

Links to Other Sites

Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

Children's Privacy

Our Service does not address anyone under the age of 18 ("Children").

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

Changes to This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact pdo@nipd.com

Ok got it!